UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Enhancing ketamine translational pharmacology via receptor occupancy normalization

Neuropharmacology, 2014-11, Vol.86, p.174-180

2014

Volltextzugriff (PDF)

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration

Journal of pharmaceutical sciences, 2016-02, Vol.105 (2), p.965-971

2016

Volltextzugriff (PDF)

Single-ion conducting polymer–silicate nanocomposite electrolytes for lithium battery applications

Electrochimica acta, 2005-03, Vol.50 (10), p.2125-2134

2005

Volltextzugriff (PDF)

In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain Barrier

Drug metabolism and disposition, 2019-04, Vol.47 (4), p.405-411

2019

Volltextzugriff (PDF)

Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF

Medical & biological engineering & computing, 2017-12, Vol.55 (12), p.2069-2077

2017

Volltextzugriff (PDF)

Impact of Recovery on Fraction Unbound Using Equilibrium Dialysis

Journal of pharmaceutical sciences, 2012-03, Vol.101 (3), p.1327-1335

2012

Volltextzugriff (PDF)

In Vitro–In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein–Cannulated Monkey

Journal of pharmaceutical sciences, 2017-03, Vol.106 (3), p.898-905

2017

Volltextzugriff (PDF)

Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting

ACS chemical neuroscience, 2021-03, Vol.12 (6), p.1007-1017

2021

Volltextzugriff (PDF)

Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer

The AAPS journal, 2014-07, Vol.16 (4), p.802-809

2014

Volltextzugriff (PDF)

Self-doped block copolymer electrolytes for solid-state, rechargeable lithium batteries

Journal of power sources, 2001-07, Vol.97, p.621-623

2001

Volltextzugriff (PDF)

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration: Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism

Journal of pharmaceutical sciences, 2016-02, Vol.105 (2), p.965-971

2016

Volltextzugriff (PDF)

Large introductory science courses & digital libraries

International Conference on Digital Libraries: Proceedings of the 5th ACM/IEEE-CS joint conference on Digital libraries; 07-11 June 2005, 2005, p.366-366

2005

Volltextzugriff (PDF)

Toward commercializable microphase -separating copolymer electrolytes for rechargeable lithium batteries

Trapa, Patrick E

2003

Volltextzugriff (PDF)

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates

EJNMMI research, 2022-03, Vol.12 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

Angewandte Chemie (International ed.), 2016-08, Vol.55 (33), p.9601-9605

International ed. in English, 2016

Volltextzugriff (PDF)

Discovery and Preclinical Characterization of 1‑Methyl‑3-(4‑methylpyridin‑3‑yl)‑6‑(pyridin‑2‑ylmethoxy)‑1H‑pyrazolo-[3,4‑b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Journal of medicinal chemistry, 2014-02, Vol.57 (3), p.861-877

2014

Volltextzugriff (PDF)

Discovery and Characterization of (R)‑6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1‑c][1,4]oxazin-4(9H)‑one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates

Journal of medicinal chemistry, 2017-09, Vol.60 (18), p.7764-7780

2017

Volltextzugriff (PDF)

[O2–17–04]: PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EFFECTS OF PF‐06648671, A NOVEL GAMMA SECRETASE MODULATOR (GSM), FOLLOWING SINGLE AND MULTIPLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS

Alzheimer's & dementia, 2017-07, Vol.13 (7S_Part_12)

2017

Volltextzugriff (PDF)

Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Journal of medicinal chemistry, 2014-02, Vol.57 (3), p.861-877

2014

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Enhancing ketamine translational pharmacology via receptor occupancy normalization

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration

Single-ion conducting polymer–silicate nanocomposite electrolytes for lithium battery applications

In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain Barrier

Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF

Impact of Recovery on Fraction Unbound Using Equilibrium Dialysis

In Vitro–In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein–Cannulated Monkey

Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting

Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer

Self-doped block copolymer electrolytes for solid-state, rechargeable lithium batteries

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration: Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism

Large introductory science courses & digital libraries

Toward commercializable microphase -separating copolymer electrolytes for rechargeable lithium batteries

Discovery of Clinical Candidate PF-06648671: A Potent γ‑Secretase Modulator for the Treatment of Alzheimer’s Disease

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Discovery and Preclinical Characterization of 1‑Methyl‑3-(4‑methylpyridin‑3‑yl)‑6‑(pyridin‑2‑ylmethoxy)‑1H‑pyrazolo-[3,4‑b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Discovery and Characterization of (R)‑6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1‑c][1,4]oxazin-4(9H)‑one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates

[O2–17–04]: PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EFFECTS OF PF‐06648671, A NOVEL GAMMA SECRETASE MODULATOR (GSM), FOLLOWING SINGLE AND MULTIPLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS

Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

Suchergebnisse filtern